MedPath

Ipratropium Bromide and Albuterol Sulfate

Ipratropium Bromide and Albuterol Sulfate Inhalation Solution, USP

Approved
Approval ID

3c64255e-074c-41f8-a344-3686a0685020

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Aug 25, 2020

Manufacturers
FDA

Cipla USA Inc.

DUNS: 078719707

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Ipratropium Bromide and Albuterol Sulfate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code69097-173
Application NumberANDA077559
Product Classification
M
Marketing Category
C73584
G
Generic Name
Ipratropium Bromide and Albuterol Sulfate
Product Specifications
Route of AdministrationRESPIRATORY (INHALATION)
Effective DateAugust 25, 2020
FDA Product Classification

INGREDIENTS (6)

SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
ALBUTEROL SULFATEActive
Quantity: 2.5 mg in 3 mL
Code: 021SEF3731
Classification: ACTIM
IPRATROPIUM BROMIDEActive
Quantity: 0.5 mg in 3 mL
Code: J697UZ2A9J
Classification: ACTIR
WATERInactive
Code: 059QF0KO0R
Classification: IACT
EDETATE DISODIUMInactive
Code: 7FLD91C86K
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Ipratropium Bromide and Albuterol Sulfate - FDA Drug Approval Details